AbbVie Reports Phase 3 EPCORE® DLBCL-1 Topline Results for Epcoritamab in Relapsed/Refractory DLBCL AbbVie today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific…
New Data Shows CAPLYTA® May Help Adults with MDD Achieve Remission Johnson & Johnson today announced a new analysis of Phase 3 data which found CAPLYTA® (lumateperone), in combination with an antidepressant,…
Opdivo® IV Infusion Approved in Taiwan in Combination with Yervoy® for Adults with Unresectable or Metastatic MSI-H/dMMR Colorectal Cancer Ono Pharmaceutical Co., Ltd. today announced that Ono Pharma Taiwan Co.,…
Celltrion Unveils Innovative Drug Pipeline and Expands U.S. Manufacturing and R&D Strategy at 44th Annual J.P. Morgan Healthcare Conference Celltrion, a leading global biopharmaceutical company, today presented key strategic priorities…
Neurocrine Biosciences Presents Head-to-Head Data Showing INGREZZA® (valbenazine) Capsules Achieve Higher VMAT2 Target Occupancy Than AUSTEDO XR Neurocrine Biosciences, Inc. today announced the presentation of the first head-to-head data comparing vesicular…
Johnson & Johnson Launches Mobile Simulator App to Empower Breast Augmentation Patients Johnson & Johnson announced the U.S. launch of the Arbrea Breast Simulator Surgeon App for Mentor, a digital consultation…
TECVAYLI® Monotherapy Shows Superior Survival vs. Standard Care in Early Relapsed, Heavily Pretreated Multiple Myeloma Johnson & Johnson, a worldwide leader in multiple myeloma therapies, today announced positive topline results…
Legend Biotech Showcases Latest Business Developments at 44th Annual J.P. Morgan Healthcare Conference Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today provided an update on…
WuXi Biologics Secures UK MHRA GMP Certification for Commercial Production of Ophthalmic Biologic WuXi Biologics a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its…
Royalty Pharma to Showcase Achievements and Share Business Update at J.P. Morgan Healthcare Conference Royalty Pharma plc today provided an update on its business performance, including recent key accomplishments. Pablo…
Biogen Secures European Commission Approval for High-Dose SPINRAZA® (nusinersen) Regimen in Spinal Muscular Atrophy Biogen Inc. today announced the European Commission (EC) has granted marketing authorization for a high dose…
BMS Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Teens with oHCM Bristol Myers Squibb today announced positive topline results from SCOUT-HCM, a Phase 3 trial evaluating Camzyos (mavacamten) in the…